analyst

Novo Nordisk shares have recouped more than 40% from their early-March low, but the stock still sits nearly…

Novo Nordisk has started selling an oral version of its blockbuster obesity drug Wegovy to private patients in…

The past month has brought some much-needed relief to Novo Nordisk shareholders. After shedding nearly a third of…

A dual catalyst – the UK launch of an oral version of Wegovy and a fresh US Medicare…

We expect to release the H1 2026 interim results of DSV A/S in the morning of 22 July…

Novo Nordisk closed the week with a 3.21% gain, pushing its shares to €38.90 on Friday. The rally…

Danish drugmaker sells Parkinson cell therapy asset to focus on metabolic disease, as Hedgeye sees 52-117% upside and…

Hedgeye sees up to 117% upside for Novo Nordisk as oral obesity pill prescriptions surge; home delivery via…

Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy’s 28% weight…

Novo Nordisk sheds last cell therapy asset to focus on metabolic diseases, as Hedgeye predicts 52-117% upside and…

Novo Nordisk shares surge 31% from March lows as Hedgeye forecasts 52-117% upside, fueled by oral obesity drug…

Geopolitical, Tensions 31.03.2026 – 05:14:44 | boerse-global.de Rising oil prices and Middle East tensions…

Novo Nordisk’s Pill Strategy Gets a Double Boost – EU Nod and Analyst Upgrade – Yet the Growth S